



**HAL**  
open science

# Invalidation of Parkinson's disease diagnosis after years of follow-up based on clinical, radiological and neurophysiological examination

Giulia Coarelli, Béatrice Garcin, Emmanuel Roze, Marie Vidailhet, Bertrand Degos

## ► To cite this version:

Giulia Coarelli, Béatrice Garcin, Emmanuel Roze, Marie Vidailhet, Bertrand Degos. Invalidation of Parkinson's disease diagnosis after years of follow-up based on clinical, radiological and neurophysiological examination. *Journal of the Neurological Sciences*, 2019, 406, pp.116454. 10.1016/j.jns.2019.116454 . hal-02962324

**HAL Id: hal-02962324**

<https://hal.sorbonne-universite.fr/hal-02962324v1>

Submitted on 9 Oct 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Invalidation of Parkinson's disease diagnosis after years of follow-up based on clinical,  
radiological and neurophysiological examination**

Giulia Coarelli<sup>a,b</sup>, Béatrice Garcin<sup>a,b</sup>, Emmanuel Roze<sup>b,c</sup>, Marie Vidailhet<sup>b,c</sup>, Bertrand Degos<sup>a,d</sup>

<sup>a</sup> Service de Neurologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP),  
Université Paris 13, 93000, Bobigny, France

<sup>b</sup> Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, CNRS UMR  
7225, Institut du Cerveau et de la Moelle Epinière, F-75013, Paris, France

<sup>c</sup> Département de Neurologie, Centre Expert de la maladie de Parkinson, Groupe Hospitalier  
Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), 75013, Paris, France

<sup>d</sup> Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary  
Research in Biology, Collège de France, CNRS UMR7241/INSERM U1050, MemoLife Labex,  
75005 Paris, France

Corresponding author: Dr. Giulia Coarelli, Institut du Cerveau et de la Moelle Epinière, UMR  
S 1127, Inserm U 1127, CNRS UMR 7225, Sorbonne Université; 47 Boulevard de l'Hôpital,  
75013, Paris, France; tel: + 33 1 57 27 46 06; email: giulia.coarelli@icm-institute.org

## **Abstract**

**Introduction:** Diagnosis of Parkinson's disease (PD) is mainly based on clinical features. Accurate neurological examination is required but dopamine transporter (DaT) single photon emission computed tomography (SPECT) could be performed to support the diagnosis in ambiguous cases. The aim of this work is to describe the characteristics of patients with a prolonged PD misdiagnosis.

**Methods:** We collected data from 24 patients initially diagnosed with PD who had an atypical long-term evolution. We analyzed demographic and clinical characteristics and antiparkinsonian drugs medication. Brain MRI, DaT-SPECT and/or accelerometry/electromyography (EMG) recording were performed in a subgroup of patients. We analyzed the causes of erroneous PD diagnosis as well as the final diagnoses.

**Results:** Mean age at PD diagnosis was  $60.4 \pm 14.8$  years. Symptoms at onset were rest tremor (n=19), gait instability (n=7) and micrographia (n=4). Mean duration before diagnosis correction was  $8.4 \pm 5.3$  years. All patients were treated by antiparkinsonian drugs with a mean daily LEVODOPA equivalent dose (LED) of  $508.1 \pm 528.4$  mg. All 18 patients who underwent DaT-SPECT had a normal result. The most frequent final diagnoses were essential tremor (n=11) and functional movement disorders (n=9).

**Conclusion:** Cases that have been initially diagnosed as PD and then progress in an atypical long-duration fashion may have been misdiagnosed. Absence of genuine bradykinesia, non-sustained response to antiparkinsonian drugs, or absence of LEVODOPA-related side effects should prompt the clinician to reappraise the diagnosis and to consider performing a DaT-SPECT.

## **Abbreviations**

DaT: dopamine transporter

EMG: electromyography

ET: essential tremor

FMD: functional movement disorders

LED: LEVODOPA equivalent dose

LRRK2: leucine-rich repeat kinase 2

MDS: Movement Disorder Society

PD: Parkinson's disease

SD: standard deviation

SWEDD: scans without evidence of dopaminergic deficit

**Keywords:** Parkinson's disease, essential tremor, functional movement disorders, DaT-SPECT

## **Introduction**

The diagnosis of Parkinson's disease (PD) is mostly based on clinical examination. It can be guided by the Movement Disorder Society (MDS) clinical diagnostic criteria [1,2], and occasionally supported by imaging studies in challenging cases. Definite diagnosis can only be achieved by *post mortem* neuropathological examination [3]. The accuracy of PD diagnosis in clinical practice is suboptimal, notably in the early stages, when manifestations of the disease have not fully emerged [4]. Initial PD diagnosis is overall reconsidered in 10-30% of the patients during the follow-up [4-7]. There is a trend towards over-diagnosis of PD [4,8] but the diagnosis accuracy seems to increase when patients are examined in a specialized Movement Disorders unit and with disease duration, as confirmed by autopsy data [9,10]. In specialized centers it is easier to access specific investigations to rule out differential diagnosis and invalidate PD diagnosis. Normal dopamine transporter (DaT) SPECT rules out PD, as reported in the MDS absolute exclusion criteria [1]. Advances in biological and radiological biomarkers research are promising, notably in the differentiation between PD and atypical parkinsonism [11]. Currently, there is no specific PD biomarker that can allow us to ascertain the diagnosis of PD in patients with a neurodegenerative disorder so that clinical diagnosis remains the gold standard.

We aimed to describe the clinical features involved in erroneous PD diagnosis during a long-term clinical follow-up and to revise diagnosis in those atypical PD patients.

## **Methods**

To describe the features involved in erroneous initial diagnosis of PD, we retrospectively analyzed a series of PD patients, who had had an atypical long-term evolution. Patients were followed up in two French sites, at Neurology Department of Pitié-Salpêtrière Hospital in Paris (n = 22) and Neurology Unit of Avicenne Hospital in Bobigny (n = 2), between 2010 and 2018.

The study was approved by the local ethics committee (CPP-IdF-Paris 6). According to the French law concerning clinical retrospective studies, a written consent of patients was not mandatory. An oral consent was nevertheless obtained for all patients. For video recording a written consent was obtained.

The atypical evolution of PD was defined by the presence of at least one of the following features: stability of neurological examination after several years of follow-up (the absence of disease stage worsening with no change in drug doses, no use of walking devices, etc.), absence of genuine bradykinesia (progressive decrements in velocity and/or amplitude movements), non-sustained response to dopaminergic treatments, absence of LEVODOPA-induced motor complications after 10 years of LEVODOPA therapy. PD diagnoses were revised by applying the PD diagnostic criteria of Postuma et al., 2015 [1]. We collected demographic, clinical, radiological and therapeutic data. Motor examination was assessed by the third section of the Unified Parkinson's Disease Rating Scale (UPDRS, max. value 108). The mean daily LEVODOPA equivalent dose (LED) was calculated for each patient. Brain MRI, Dat-SPECT and/or accelerometry/electromyography (EMG) recordings were performed in a subgroup of patients, when diagnostic uncertainty persisted after a rigorous clinical examination based on the latest PD criteria [1]. Data are expressed as the mean  $\pm$  standard deviation (SD) or frequency (n).

## **Results**

PD diagnosis was reassessed in 24 patients (19 women and 5 men). Demographic, clinical and radiological characteristics of all patients are summarized in Table 1. The initial PD diagnosis was performed in the half of patients by family physician and in the other half by a neurologist who did not work in a movement disorder center. Mean age at PD diagnosis was  $60.4 \pm 14.8$  years, and mean age at examination was  $68.8 \pm 16.3$  years with a mean disease duration of 8.4

$\pm 5.3$  years. Symptoms at onset (isolated or combined), were rest tremor ( $n = 19$ ), gait instability ( $n = 7$ ), akineto-rigid syndrome ( $n=4$ ), and/or micrographia ( $n = 4$ ). UPDRS was available from referral letters in only 7 patients at the time of reassessment, with a mean score of  $12.9 \pm 7.7$ , ranging from 3 to 25 (max value 108). During neurological reevaluation, we assessed UPDRS only in 4 patients with a mean score of  $10.5 \pm 5.2$ ; for the other patients, the scale was not performed since parkinsonian syndrome was absent or not obvious. All patients were receiving oral antiparkinsonian drugs with a mean daily LED of  $508.1 \pm 528.4$  mg. Amongst them, eight patients were receiving high dose of LED ( $\geq 600$  mg), without any clinical improvement. The main clinical features which led us to question the diagnosis were: paucity of bradykinetic features ( $n=13$ ), non-sustained response to antiparkinsonian drugs ( $n=6$ ), absence of side effects (dyskinesia, motor fluctuations, wearing off) of antiparkinsonian drugs despite long disease duration ( $n=6$ ), and evidence for distractibility and/or suggestibility during clinical examination ( $n=8$ ).

DaT-SPECT was performed and normal in 18 patients. Twelve patients underwent a brain MRI, showing vascular leukoencephalopathy signs ( $n = 5$ ), bilateral pallidal lesions ( $n = 1$ ), imaging findings of normal pressure hydrocephalus ( $n = 1$ ) and cerebral falx meningioma ( $n = 1$ ). MRI was normal in four patients. EMG and accelerometry were performed in two patients and showed findings inconsistent with a parkinsonian tremor, but rather a typical pattern of essential tremor (ET) recording in one patient, and fluctuations of the tremor frequency and intensity, influenced by distraction, in another. Based on clinical reevaluation and additional examinations, we revised the initial PD diagnosis. Final diagnoses were ET ( $n= 11$ ), functional movement disorders (FMD) ( $n= 9$ ), and individual cases of normal pressure hydrocephalus, anoxic brain injury as revealed by bilateral pallidal lesions on brain MRI, previous neuroleptic drug treatment, and association of lumbar spinal stenosis and cerebral falx meningioma. An autosomal dominant transmission pattern was observed amongst the 5/11 ET cases. Withdrawal

of dopaminergic drugs did not result in worsening of the symptoms in any patient (24/24). Video 1 shows one patient with FMD diagnosis after evolution over 15-year period and no improvement with LEVODOPA treatment. The absence of characteristic bradykinesia, without decrease in hand movements speed and amplitude, can be observed in the video.

## **Discussion**

We report data from 24 patients with prolonged PD misdiagnosis, who underwent a late clinical reassessment in a specialized Movement Disorders clinic. This case series underlines the importance of reassessing PD patients when the course of the disease is unexpected.

In our cohort, ET and FMD were the most frequent diagnoses. ET has previously been reported as the main differential diagnosis in other series of presumed PD patients [5]. One reason is that ET is one of the most frequent movement disorder with an overall prevalence of 0.9%, which increases with age [12]. Neurologists should be cognizant of the key clinical features which assist in establishing the correct ET diagnosis [13]. Likewise, functional neurological disorders are frequent in clinical practice, accounting for 4-16% of newly referred neurological patients [14], or even more in specialized Movement Disorders clinics. These disorders are frequently unrecognized for a long period possibly due to limited clinical experience of neurologists and psychiatrists with this disorder. This diagnosis delay often results in stress and disability, thereby representing a considerable economic burden [15]. Of note, tremor and dystonia are the main clinical presentation among FMD [15, 16]. When examining patients with tremor, clinicians should look for positive signs of FMDs notably distractibility, entrainment suggestibility and variability [17]. EMG and accelerometry can support the clinical diagnosis of functional tremor or dystonia [18] and may be helpful in explaining the diagnosis as the starting point of the therapeutic strategy.



To avoid misdiagnosis in PD, clinicians should know how to recognize the classical features of parkinsonian syndrome. For example, progressive reduction in speed and amplitude of repetitive movements is characteristic of parkinsonian brady- and hypokinesia, respectively, while it is not present in patients with movement limitations caused by osteoarticular pathologies, spastic hypertonia, or functional slowness. Moreover, in functional parkinsonism, tremor usually involves the limb rather than the hand, with fluctuations in rhythm and direction, rigidity is due to an active resistance and not associated with cogwheel, freezing of gait is absent, handwriting is impaired without the typical micrographia [19]. In addition, disability is faster attained and is not proportionate to what could have been expected from clinical examination. Interestingly, functional movement disorders can coexist with PD and are more frequent in PD and dementia with Lewy bodies than in other neurodegenerative disorders and psychiatric diseases [20]. Finally, we suggest that the diagnosis of PD should be reappraised when LEVODOPA treatment is ineffective and when there is no motor LEVODOPA-induced complications. These complications occur in about 50% of PD patients after 5 years [21] and in 90% of patients after 10 years of evolution. We did not detect any atypical parkinsonian cases. It may be explained by the low prevalence of these diseases compared to ET and FMD, and by the limited number of subjects included in our study. Moreover, in atypical parkinsonian syndromes, additional symptoms and signs (red flags), as well as the rapid course of the disease, usually induce a faster correction of the misdiagnosis.

Imaging studies may be required to correct a wrong diagnosis of PD. Indeed, brain MRI may guide towards differential diagnoses such as atypical parkinsonian syndromes, as may [18F]-Fluorodeoxyglucose ([18F]-FDG) PET and sympathetic cardiac [123I]-Metaiodobenzylguanidine ([123I]-MIBG) scintigraphy [6, 22]. DaT-SPECT can be helpful in doubtful cases [7,8]. Normal DaT-SPECT usually eliminates PD diagnosis, and conversely, when abnormal, it supports physician confidence in PD diagnosis with consistent modifications

in clinical management [7]. However, patients with suspected PD, whose DaT-SPECT show no evidence of dopaminergic deficit (SWEDD) still represent a controversy. It seems clear that the majority of SWEDD patients are misdiagnosed as PD [23, 24], and wrongly enrolled in clinical trials [19, 25]. Some exceptions exist as reported for SWEDD in a patient carrying leucine-rich repeat kinase 2 (LRRK2) p.G2019S mutation [26]. In a three-year longitudinal study, specificity of DaT-SPECT to detect nigrostriatal denervation was almost 100%, without modification all along the study, showing overdiagnosis of PD at the baseline [8]. However, normal DaT-SPECT has been described at the early stages of the disease [27] and conversion of normal to abnormal scans can occur during follow-up [28]. DaT-SPECT can support the clinical and electrophysiological diagnosis of functional parkinsonism hence limiting misdiagnosis [29].

Misdiagnosis has a significant impact on treatment and prognosis for patients but also influences the outcomes of epidemiological and clinical studies. Misdiagnosis rates should be taken into account to calculate sample size, especially when early-onset patients are included in clinical researches. For this purpose, the MDS task force proposed criteria for clinically established early PD [30] with modifications of the MDS criteria [1], as shown in Table 2. These criteria have a high specificity (95.4%) in early PD patients and are a useful tool to accurately recruit patients in clinical trials.

**Author Disclosures:** the authors report no disclosure.

**Conflict of interest:** On behalf of all authors, the corresponding author states that there is no conflict of interest.

**Acknowledgements:** the authors are grateful to the patients. The authors thank Sébastien Valverde for English editing.

**Study funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Video 1-2. Patient with functional movement disorders diagnosis showing absence of bradykinesia (video 1) and evidence of normal right upper limb mobility suggesting distractibility (video 2).**

Sex	Age at PD diagnosis (y)	Clinical examination	LED (mg/d)	DD (y)	DaT-SPECT	Brain MRI	accelerometry/EMG	Atypical features	Reason for diagnosis reevaluation	Final diagnosis
F	66	Akineto-rigid syndrome, jaw and UL rest tremor, UL postural tremor, gait impairment, orthostatic hypotension	300	12	N	N	nd	12 years evolution without LID or motor fluctuations	normal DaT-SPECT	ET
F	48	Akinesia, rest tremor, gait impairment, swallowing disorder, urinary dysfunction, restless legs syndrome	450	15	N	nd	nd	15 years evolution with stability of symptoms without LID	Distractibility at examination, two DaT-SPECT negative	FMD
F	46	Akineto-rigid syndrome, rest tremor, swallowing disorder, urinary dysfunction, gait impairment	2711	6	N	nd	nd	Stability of symptoms, no motor fluctuations	Distractibility during neurological evaluation, normal DaT-SPECT	FMD
F	32	Akineto-rigid syndrome, rest tremor	625	6	N	nd	nd	Stability of symptoms, no motor fluctuations	Distractibility during neurological evaluation, normal DaT-SPECT	FMD
F	58	Akineto-rigid syndrome, rest tremor, gait impairment, restless legs syndrome	555	15	N	VLE	nd	15 years evolution without clinical worsening	Neuroleptic intake	Iatrogenic
F	55	Akineto-rigid syndrome, rest tremor	245	2	nd	nd	nd	Stability of symptoms, no motor fluctuations	Distraction and suggestibility during clinical examination	FMD
F	73	UL rest and postural tremor	52	3	N	nd	nd	Predominant tremor with no fatigable bradykinesia	normal DaT-SPECT	ET
F	68	UL rest and postural tremor, gait impairment	257.5	15	Nd	VLE	nd	Predominant tremor with no fatigable bradykinesia	12 years evolution without treatment positive effect	ET
M	55	Gait impairment, sensory dysfunction	100	5	N	Nd	nd	Stability of symptoms, no motor fluctuations	Distraction and suggestibility during clinical examination, normal DaT-SPECT	FMD

F	46	Akineto-rigid syndrome, gait impairment	840	6	N	N	nd	Stability of symptoms, no motor fluctuations, no response to treatment	Distraction and suggestibility during clinical examination, normal DaT-SPECT	FMD
F	63	UL rest and postural tremor	750	10	N	nd	nd	Stability of symptoms, no motor fluctuations, no fatigable bradykinesia, no response to treatment	Normal DaT-SPECT	ET
M	49	Akineto-rigid syndrome, rest tremor, pyramidal syndrome, gait impairment, urinary dysfunction, sleep disorders	105	7	N	BPL	nd	Mild extrapyramidal syndrome, cerebellar and pyramidal syndrome	BPL at brain MRI	Anoxic brain injury (bilateral pallidal lesions)
F	75	Akineto-rigid syndrome, pyramidal syndrome gait impairment, urinary dysfunction, orthostatic hypotension	850	9	N	CFM	nd	Aggravation of pyramidal syndrome and gait impairment, no response to treatment	Lumbar spinal stenosis at spine MRI; cerebral falx meningioma at brain MRI	Lumbar spinal stenosis
F	44	Akineto-rigid syndrome, gait impairment, limb dystonia, urinary dysfunction, sleep disorders	700	11	N	N	nd	Long term stability of symptoms, no motor fluctuations, no response to treatment	Distraction and suggestibility during clinical examination, normal DaT-SPECT	FMD
F	74	UL rest and postural tremor, gait impairment	600	10	N	VLE	nd	10 years evolution without LID or motor fluctuations	Normal DaT-SPECT	ET
F	81	Akinesia, UL rest and postural tremor	500	3	nd	nd	nd	predominant tremor with no fatigable bradykinesia, no response to treatment	Second clinical evaluation positive for ET and negative LEVODOPA - sensibility	ET
M	75	Gait impairment, urinary dysfunction, cognitive dysfunction	250	4	nd	NPH	nd	Gait impairment aggravation, cognitive decline, urinary dysfunction	NPH at brain MRI	NPH
F	30	UL rest and postural tremor, gait impairment, sleep disorders	54	2	N	N	nd	Predominant tremor with no fatigable bradykinesia	Normal DaT-SPECT	ET
M	75	UL rest and postural tremor	608	15	nd	nd	nd	Predominant tremor with no fatigable bradykinesia	Long term stability of symptoms, no motor fluctuations	ET

F	66	UL postural tremor	392.5	20	N	nd	nd	Predominant tremor with no fatigable bradykinesia, primidone efficacy	Normal DaT-SPECT	ET
F	70	Rest and postural tremor	300	15	N	VLE	Rest, postural and action tremor with frequency variability (4.5-6 Hz) and loss by distraction	Long term stability of symptoms, no motor fluctuations, no response to treatment	Distraction and suggestibility during clinical examination	FMD
M	52	UL postural tremor	450	5	N	Nd	UL attitude tremor with frequency of 6 Hz associated to rest tremor	Predominant tremor with no fatigable bradykinesia, 5 years evolution without LID or motor fluctuations	Normal DaT-SPECT and typical accelerometry EMG	ET
F	64	Dysphonia, head and UL rest and postural tremor	375	3	N	VLE	nd	Stability of symptoms, no motor fluctuations	Distraction and suggestibility during clinical examination	FMD
F	84	UL, jaw, head rest and postural tremor	125	3	nd	Nd	nd	Predominant tremor with no fatigable bradykinesia	Stability of symptoms, no motor fluctuations	ET

**Table 1. Demographic, clinical and radiological characteristics of our cohort of patients.**

**Abbreviations:** BPL: bilateral pallidal lesions; CFM: cerebral falx meningioma; DD: disease duration; ET: essential tremor; F: female; FMD: functional movement disorders; LID: LEVODOPA-induced dyskinesia; M: male; N: normal; nd: not done; NPH: normal pressure hydrocephalus; UL: upper limb; VLE: vascular leukoencephalopathy.

**Table 2. Differences between the new MDS criteria for clinically established early PD and MDS clinical diagnostic criteria for PD.**

	<b>MDS Clinical Diagnostic Criteria for Clinically Established PD [1]</b>	<b>MDS Clinical Diagnostic Criteria for Clinically Probable PD [1]</b>	<b>MDS Criteria for Clinically Established Early PD (&lt;5 years) [30]</b>
<b>Essential criterion</b>	Parkinsonism (bradykinesia, in combination with at least 1 of rest tremor or rigidity)	Parkinsonism (bradykinesia, in combination with at least 1 of rest tremor or rigidity)	Parkinsonism (bradykinesia, in combination with at least 1 of rest tremor or rigidity)
<b>Supportive criteria</b>	At least two <ul style="list-style-type: none"> <li>- Clear and dramatic beneficial response to dopaminergic therapy</li> <li>- Presence of LEVODOPA-induced dyskinesia</li> <li>- Rest tremor of a limb</li> <li>- Presence of either olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy</li> </ul>	If 1 red flag → at least 1 supportive criterion If 2 red flags → at least 2 supportive criteria are needed No more than 2 red flags	Removed
<b>Red flags</b>	No red flags <ul style="list-style-type: none"> <li>- Rapid progression of gait impairment requiring regular use of wheelchair within 5 y of onset</li> <li>- A complete absence of progression of motor symptoms or signs over 5 or more y unless stability is related to treatment</li> <li>- Early bulbar dysfunction within first 5 y</li> <li>- Inspiratory respiratory dysfunction</li> <li>- Severe autonomic failure in the first 5 y of disease</li> <li>- Recurrent (&gt;1/y) falls because of impaired balance within 3 y of onset</li> <li>- Disproportionate anterocollis (dystonic) or contractures of hand or feet within the first 10 y</li> <li>- Absence of any of the common non motor features of disease despite 5 y disease duration</li> <li>- Otherwise-unexplained pyramidal tract signs</li> <li>- Bilateral symmetric parkinsonism</li> </ul>		Red flags considered as absolute exclusions
<b>Exclusion criteria</b>	Absence of absolute exclusion criteria <ul style="list-style-type: none"> <li>- Unequivocal cerebellar abnormalities</li> <li>- Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades</li> <li>- Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia, within the first 5 y of disease</li> <li>- Parkinsonian features restricted to the lower limbs for more than 3 y</li> <li>- Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism</li> </ul>	Absence of absolute exclusion criteria (9 exclusion criteria)	Absence of absolute exclusion criteria <ul style="list-style-type: none"> <li>- Unequivocal cerebellar abnormalities</li> <li>- Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades</li> <li>- Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia</li> <li>- Parkinsonian features restricted to the lower limbs</li> <li>- Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism</li> <li>- Absence of observable response to high-dose LEVODOPA despite at least moderate severity of disease</li> </ul>



	<ul style="list-style-type: none"> <li>- Absence of observable response to high-dose LEVODOPA despite at least moderate severity of disease</li> <li>- Unequivocal cortical sensory loss, clear limb ideomotor apraxia, or progressive aphasia</li> <li>- Normal functional neuroimaging of the presynaptic dopaminergic system</li> <li>- Documentation of an alternative condition known to produce parkinsonism</li> </ul>		<ul style="list-style-type: none"> <li>- Unequivocal cortical sensory loss, clear limb ideomotor apraxia, or progressive aphasia</li> <li>- Normal functional neuroimaging of the presynaptic dopaminergic system</li> <li>- Gait impairment requiring regular use of wheelchair</li> <li>- Severe dysphonia/dysarthria and/or severe dysphagia</li> <li>- Inspiratory respiratory dysfunction</li> <li>- Severe autonomic failure</li> <li>- Recurrent (&gt;1/y) falls because of impaired balance</li> <li>- Disproportionate anterocollis (dystonic) or contractures of hand or feet</li> <li>- Absence of any of the common non motor features of disease</li> <li>- Otherwise-unexplained pyramidal tract signs</li> <li>- Bilateral symmetric parkinsonism</li> <li>- Documentation of an alternative condition known to produce parkinsonism</li> </ul>
<b>Disease duration components</b>	Present in red flags and exclusion criteria	Present in red flags and exclusion criteria	Removed
<b>Specificity/Sensitivity (%)</b>	98.4/59.3 [2]	88.5/94.5 [2]	95.4/69.8

**Abbreviations:** MDS: Movement Disorder Society; PD: Parkinson’s disease; y: years

## References (max. 30)

- [1] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR (2015) Adler CH, Deuschl G, MDS clinical diagnostic criteria for Parkinson's disease, *Mov Disord.* 30:1591-601.
- [2] Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D (2018) Validation of the MDS clinical diagnostic criteria for Parkinson's disease, *Mov Disord.* 33:1601-1608.
- [3] Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, *Brain* 125:861-70.
- [4] Joutsa J, Gardberg M, Røyttä M, Kaasinen V (2014) Diagnostic accuracy of parkinsonism syndromes by general neurologists, *Parkinsonism Relat Disord.* 20:840-4.
- [5] Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson's disease in the community? *J Neurol Neurosurg Psychiatry* 73:529–534.
- [6] Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M (2013) EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease, *Eur J Neurol.* 20:16-34.
- [7] Sadasivan S, Friedman JH (2015) Experience with DaTscan at a tertiary referral center, *Parkinsonism Relat Disord.* 21:42-5.

- [8] Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG (2009) Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT, *Mov Disord.* 24:500-8.
- [9] Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study, *Neurology* 83:406-12.
- [10] Beach TG, Adler CH (2018) Importance of low diagnostic Accuracy for early Parkinson's disease, *Mov Disord.* 33:1551-1554.
- [11] Andersen AD, Binzer M, Stenager E, Gramsbergen JB (2017) Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review, *Acta Neurol Scand.* 135:34-56.
- [12] Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor, *Mov Disord.* 25:534-41.
- [13] Louis ED (2014) Twelve clinical pearls to help distinguish essential tremor from other tremors, *Expert Rev Neurother.* 14:1057-65.
- [14] Stone J, Carson A, Duncan R, Roberts R, Warlow C, Hibberd C, Coleman R, Cull R, Murray G, Pelosi A, Cavanagh J, Matthews K, Goldbeck R, Smyth R, Walker J, Sharpe M (2010) Who is referred to neurology clinics? The diagnoses made in 3781 new patients, *Clin Neurol Neurosurg* 112:747-751.

- [15] Garcin B (2018) Motor functional neurological disorders: An update, *Rev Neurol.* 4:203-211.
- [16] Thomas M, Vuong KD, Jankovic J (2006) Long-term prognosis of patients with psychogenic movement disorders, *Parkinsonism Relat Disord.* 12:382-7.
- [17] Gupta A, Lang AE (2009) Psychogenic movement disorders, *Curr Opin Neurol.* 22:430-6.
- [18] Hallett M (2010) Physiology of psychogenic movement disorders, *J Clin Neurosci.* 17:959-65.
- [19] Jankovic J (2011) Diagnosis and treatment of psychogenic parkinsonism, *J Neurol Neurosurg Psychiatry* 82:1300-3.
- [20] Onofrj M, Thomas A, Tiraboschi P, Wenning G, Gambi F, Sepede G, Di Giannantonio M, Di Carmine C, Monaco D, Maruotti V, Ciccocioppo F, D'Amico MC, Bonanni L (2011) Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology, *J Neurol Sci.* 15:166-71.
- [21] Wenning G, Gambi F, Sepede G, Di Giannantonio M, Di Carmine C, Monaco D, Maruotti V, Ciccocioppo F, D'Amico MC, Bonanni L, Ray Chaudhuri K, Poewe W, Brooks D (2018) Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features, *Mov Disord.* 33:909-919.
- [22] Thobois S, Prange S, Scheiber C, Emmanuel Broussolle (2018) What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective, *Parkinsonism Relat Disord.* Aug 30.

- [23] Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators (2014) Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, *Neurology* 82:1791-7.
- [24] Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP (2016) What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies, *J Neurol Neurosurg Psychiatry* 87:319-23.
- [25] Parkinson Progression Marker Initiative (2011) The Parkinson Progression Marker Initiative (PPMI), *Prog Neurobiol.* 95:629-35.
- [26] Wile DJ, Dinelle K, Vafai N, McKenzie J, Tsui JK, Schaffer P, Ding YS, Farrer M, Sossi V, Stoessl AJ (2016) A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier, *Mov Disord.* 31:405-9.
- [27] Stoessl AJ (2010) Scans without evidence of dopamine deficiency: the triumph of careful clinical assessment, *Mov Disord.* 25:529-30.
- [28] Menéndez-González M, Tavares F, Zeidan N, Salas-Pacheco JM, Arias-Carrión O (2014) Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study, *Front Aging Neurosci.* 6:56.
- [29] Benaderette S, Zanotti Fregonara P, Apartis E, Nguyen C, Trocetto JM, Remy P, Devaux JY, Askienazy S, Vidailhet M (2006) Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy, *Mov Disord.* 3:310-7.
- [30] Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel

W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB (2018) Movement disorder society criteria for clinically established early Parkinson's disease, *Mov Disord.* 33:1643-1646.